… omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant
to or intolerant of tyrosine kinase inhibitors. Eighteen percent of chronic phase CML patients …

… to evaluate appropriate time points for mutation analysis of chronic myeloid leukemia. … In
total, 961 blood samples obtained from 605 chronic-phase chronic myeloid leukemia patients …

… Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by the BCR-ABL1
fusion gene generation as a consequence of the t(9;22)(q34;q11) rearrangement. The …

… The NCCN guideline recommends imatinib (400 mg QD) and second-generation TKIs (dasatinib
(100 mg QD), nilotinib (300 mg BID) and bosutinib (400 mg QD) as appropriate options …

… This manuscript presents the scientific insights of the participating attendees, panel … [14]
Moreover, as per NCCN guidelines, B-cells presenting with a CLL/SLL phenotype may be found …

… Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology. J
Natl … NCCN guidelines insights: Myeloproliferative neoplasms, version 2.2018. J Natl Compr …

… This manuscript presents the scientific insights of the participating attendees, panel …
Moreover, as per NCCN guidelines, B-cells presenting with a CLL/SLL phenotype may be …

… Chronic myeloid leukemia (CML) is a hematological neoplasm that is characterized by
the presence of the translocation t(9;22)(q34;q11) or Philadelphia chromosome (Ph+), which …

… acute lymphoblastic leukemia and acute myeloid leukemia. … testing are recommended by
NCCN guidelines for use in risk … These changes potentially offer insights that could eventually …

… Tyrosine kinase inhibitors (TKIs) have dramatically impacted on the management and
outcome of patients with chronic myeloid leukemia (CML). Long-term overall survival (OS) rates …